Literature DB >> 25428390

Overexpression of BAALC: clinical significance in Chinese de novo acute myeloid leukemia.

Jing-Dong Zhou1, Lei Yang, Ying-Ying Zhang, Jing Yang, Xiang-Mei Wen, Hong Guo, Dong-Ming Yao, Ji-Chun Ma, Qin Chen, Jiang Lin, Jun Qian.   

Abstract

To investigate the expression of brain and acute leukemia, cytoplasmic (BAALC) and analyze its clinical significance in Chinese de novo acute myeloid leukemia (AML). Real-time quantitative PCR (RQ-PCR) was carried out to detect BAALC transcript level in 121 de novo AML patients and 41 normal controls. BAALC transcript level in AML patients was significantly up-regulated compared with normal controls (P < 0.001). Patients with high BAALC expression had significantly older age than those with low BAALC expression (P = 0.021). The percentage of blasts in bone marrow of the BAALC high-expressed patients was significantly higher than that in the low-expressed patients (P < 0.001). The incidence of BAALC overexpression was significantly higher in M0/M1 (8/9, 89 %) and M2 subtypes (33/48, 68 %) than in M3 subtype (6/27, 22 %) (P < 0.001). The frequency of IDH1/2 wild type in CN-AML patients with high BAALC expression was significantly higher than those with low BAALC expression (P = 0.031). BAALC high-expressed patients had a significantly lower complete remission than low-expressed patients in both entire AML cohort and CN-AML (P = 0.013 and 0.029, respectively). Furthermore, both whole AML cohort and CN-AML patients with high BAALC expression showed a shorter overall survival than those with low BAALC expression (P = 0.002 and 0.008, respectively). Multivariate analysis confirmed high BAALC expression as an independent adverse prognostic factor in both AML and CN-AML patients. Our study indicates that overexpression of BAALC serves as an independent prognostic biomarker in both whole AML cohort and CN-AML patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25428390     DOI: 10.1007/s12032-014-0386-9

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  31 in total

Review 1.  Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?

Authors:  Krzysztof Mrózek; Guido Marcucci; Peter Paschka; Susan P Whitman; Clara D Bloomfield
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

2.  BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Authors:  Sebastian Schwind; Guido Marcucci; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Kelsi B Holland; Dean Margeson; Heiko Becker; Susan P Whitman; Yue-Zhong Wu; Klaus H Metzeler; Bayard L Powell; Jonathan E Kolitz; Thomas H Carter; Joseph O Moore; Maria R Baer; Andrew J Carroll; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  Blood       Date:  2010-09-14       Impact factor: 22.113

Review 3.  Acute myeloid leukaemia.

Authors:  Elihu Estey; Hartmut Döhner
Journal:  Lancet       Date:  2006-11-25       Impact factor: 79.321

4.  RAS mutation analysis in a large cohort of Chinese patients with acute myeloid leukemia.

Authors:  Xiaofei Yang; Jun Qian; Aining Sun; Jiang Lin; Gaofei Xiao; Jia Yin; Suning Chen; Depei Wu
Journal:  Clin Biochem       Date:  2013-01-11       Impact factor: 3.281

5.  A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 AML patients in China.

Authors:  Jine Zheng; Xingbing Wang; Yu Hu; Jing Yang; Jun Liu; Yanli He; Qing Gong; Junxia Yao; Xiaoqing Li; Wen Du; Shiang Huang
Journal:  Cytometry B Clin Cytom       Date:  2008-01       Impact factor: 3.058

6.  BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.

Authors:  Claudia D Baldus; Stephan M Tanner; Amy S Ruppert; Susan P Whitman; Kellie J Archer; Guido Marcucci; Michael A Caligiuri; Andrew J Carroll; James W Vardiman; Bayard L Powell; Steven L Allen; Joseph O Moore; Richard A Larson; Jonathan E Kolitz; Albert de la Chapelle; Clara D Bloomfield
Journal:  Blood       Date:  2003-05-15       Impact factor: 22.113

7.  ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.

Authors:  Klaus H Metzeler; Annika Dufour; Tobias Benthaus; Manuela Hummel; Maria-Cristina Sauerland; Achim Heinecke; Wolfgang E Berdel; Thomas Büchner; Bernhard Wörmann; Ulrich Mansmann; Jan Braess; Karsten Spiekermann; Wolfgang Hiddemann; Christian Buske; Stefan K Bohlander
Journal:  J Clin Oncol       Date:  2009-09-14       Impact factor: 44.544

8.  BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients.

Authors:  Daniela Damiani; Mario Tiribelli; Alessandra Franzoni; Angela Michelutti; Dora Fabbro; Margherita Cavallin; Eleonora Toffoletti; Erica Simeone; Renato Fanin; Giuseppe Damante
Journal:  Am J Hematol       Date:  2013-07-23       Impact factor: 10.047

9.  Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia.

Authors:  Yun Li; Jiang Lin; Jing Yang; Jun Qian; Wei Qian; Dong-Ming Yao; Zhao-Qun Deng; Qing Liu; Xing-Xing Chen; Dong Xie; Cui An; Chun-Yan Tang
Journal:  Leuk Res       Date:  2013-09-30       Impact factor: 3.156

10.  U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Jun Qian; Dong-ming Yao; Jiang Lin; Wei Qian; Cui-zhu Wang; Hai-yan Chai; Jing Yang; Yun Li; Zhao-qun Deng; Ji-chun Ma; Xing-xing Chen
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

View more
  9 in total

1.  DLX4 hypermethylation is a prognostically adverse indicator in de novo acute myeloid leukemia.

Authors:  Jing-Dong Zhou; Ting-Juan Zhang; Yu-Xin Wang; Dong-Qin Yang; Lei Yang; Ji-Chun Ma; Xiang-Mei Wen; Jing Yang; Jiang Lin; Jun Qian
Journal:  Tumour Biol       Date:  2016-01-11

2.  Patterns of Transposable Element Expression and Insertion in Cancer.

Authors:  Evan A Clayton; Lu Wang; Lavanya Rishishwar; Jianrong Wang; John F McDonald; I King Jordan
Journal:  Front Mol Biosci       Date:  2016-11-16

3.  Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.

Authors:  Jing-Dong Zhou; Ting-Juan Zhang; Xi-Xi Li; Ji-Chun Ma; Hong Guo; Xiang-Mei Wen; Wei Zhang; Lei Yang; Yang Yan; Jiang Lin; Jun Qian
Journal:  J Cell Mol Med       Date:  2017-04-27       Impact factor: 5.310

4.  Epigenetic dysregulation of NKD2 is a valuable predictor assessing treatment outcome in acute myeloid leukemia.

Authors:  Xi-Xi Li; Jing-Dong Zhou; Ting-Juan Zhang; Lei Yang; Xiang-Mei Wen; Ji-Chun Ma; Jing Yang; Zhi-Hui Zhang; Jiang Lin; Jun Qian
Journal:  J Cancer       Date:  2017-02-11       Impact factor: 4.207

5.  Overexpression of lncRNA PANDAR predicts adverse prognosis in acute myeloid leukemia.

Authors:  Lan Yang; Jing-Dong Zhou; Ting-Juan Zhang; Ji-Chun Ma; Gao-Fei Xiao; Qin Chen; Zhao-Qun Deng; Jiang Lin; Jun Qian; Dong-Ming Yao
Journal:  Cancer Manag Res       Date:  2018-10-29       Impact factor: 3.989

6.  MicroRNA-335/ID4 dysregulation predicts clinical outcome and facilitates leukemogenesis by activating PI3K/Akt signaling pathway in acute myeloid leukemia.

Authors:  Jing-Dong Zhou; Xi-Xi Li; Ting-Juan Zhang; Zi-Jun Xu; Zhi-Hui Zhang; Yu Gu; Xiang-Mei Wen; Wei Zhang; Run-Bi Ji; Zhao-Qun Deng; Jiang Lin; Jun Qian
Journal:  Aging (Albany NY)       Date:  2019-05-30       Impact factor: 5.682

7.  Down-regulation of miR-29c is a prognostic biomarker in acute myeloid leukemia and can reduce the sensitivity of leukemic cells to decitabine.

Authors:  Li-Juan Tang; Guo-Kang Sun; Ting-Juan Zhang; De-Hong Wu; Jing-Dong Zhou; Bei-Bei Ma; Zi-Jun Xu; Xiang-Mei Wen; Qin Chen; Dong-Ming Yao; Jun Qian; Ji-Chun Ma; Jiang Lin
Journal:  Cancer Cell Int       Date:  2019-07-10       Impact factor: 5.722

8.  KRAS overexpression independent of RAS mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia.

Authors:  Jing-Dong Zhou; Dong-Ming Yao; Xi-Xi Li; Ting-Juan Zhang; Wei Zhang; Ji-Chun Ma; Hong Guo; Zhao-Qun Deng; Jiang Lin; Jun Qian
Journal:  Oncotarget       Date:  2017-08-02

9.  1H, 13C, and 15N Backbone assignments of the human brain and acute leukemia cytoplasmic (BAALC) protein.

Authors:  Andras Lang; Amit Kumar; Jan Jirschitzka; Frank Bordusa; Oliver Ohlenschläger; Christoph Wiedemann
Journal:  Biomol NMR Assign       Date:  2020-04-02       Impact factor: 0.746

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.